scholarly journals Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research

2016 ◽  
Vol 22 (7) ◽  
pp. 1306-1312 ◽  
Author(s):  
Christopher Strouse ◽  
Paul Richardson ◽  
Grant Prentice ◽  
Sandra Korman ◽  
Robin Hume ◽  
...  
Keyword(s):  
Marrow Transplant ◽  
Exploratory Analysis ◽  
Occlusive Disease ◽  
Blood And Marrow Transplant ◽  
Using Data

scholarly journals The importance of early intervention in the treatment of hepatic veno-occlusive disease

2019 ◽  
Vol 8 (2) ◽  
pp. IJH15
Author(s):  
Antonio Pagliuca
Keyword(s):  
Early Intervention ◽  
European Society ◽  
Marrow Transplant ◽  
Occlusive Disease ◽  
College Hospital ◽  
Hematopoietic Stem ◽  
The Past ◽  
Blood And Marrow Transplant ◽  
King's College ◽  
Severity Grading

Antonio Pagliuca is Professor of hematopoietic stem cell transplantation at King’s College London (UK) and medical director at King’s College Hospital where, until last year, he had been the transplant director for the past 24 years. He also has roles within NHS England as national clinical lead for regenerative medicine and is a trustee on both the Anthony Nolan trust (London, UK) and Leukemia UK (London, UK). Here he speaks to Commissioning Editor Jennifer Straiton and discusses the interim results of the DEFIFrance study, recently presented at the European Society for Blood and Marrow Transplant (EBMT), which looked at the real-world use of the European Society for Blood and Marrow Transplant severity grading criteria. The study investigates the use of defibrotide as a treatment of patients with post-transplant hepatic veno-occlusive disease and demonstrates how it can benefit from early intervention.

Quality of inpatient antimicrobial use in hematology and oncology patients

2021 ◽  
pp. 1-10
Author(s):  
Abby P. Douglas ◽  
Lisa Hall ◽  
Rodney S. James ◽  
Leon J. Worth ◽  
Monica A. Slavin ◽  
...  
Keyword(s):  
Marrow Transplant ◽  
Antifungal Prophylaxis ◽  
Neutropenic Fever ◽  
Antibacterial Prophylaxis ◽  
Separate Analysis ◽  
Prescribing Practices ◽  
Oncology Patients ◽  
Antimicrobial Prescribing ◽  
Using Data ◽  
To Receive

Abstract Objectives: To compare antimicrobial prescribing practices in Australian hematology and oncology patients to noncancer acute inpatients and to identify targets for stewardship interventions. Design: Retrospective comparative analysis of a national prospectively collected database. Methods: Using data from the 2014–2018 annual Australian point-prevalence surveys of antimicrobial prescribing in hospitalized patients (ie, Hospital National Antimicrobial Prescribing Survey called Hospital NAPS), the most frequently used antimicrobials, their appropriateness, and guideline concordance were compared among hematology/bone marrow transplant (hemBMT), oncology, and noncancer inpatients in the setting of treatment of neutropenic fever and antibacterial and antifungal prophylaxis. Results: In 454 facilities, 94,226 antibiotic prescriptions for 62,607 adult inpatients (2,230 hemBMT, 1,824 oncology, and 58,553 noncancer) were analyzed. Appropriateness was high for neutropenic fever management across groups (83.4%–90.4%); however, hemBMT patients had high rates of carbapenem use (111 of 746 prescriptions, 14.9%), and 20.2% of these prescriptions were deemed inappropriate. Logistic regression demonstrated that hemBMT patients were more likely to receive appropriate antifungal prophylaxis compared to oncology and noncancer patients (adjusted OR, 5.3; P < .001 for hemBMT compared to noncancer patients). Oncology had a low rate of antifungal prophylaxis guideline compliance (67.2%), and incorrect dosage and frequency were key factors. Compared to oncology patients, hemBMT patients were more likely to receive appropriate nonsurgical antibacterial prophylaxis (aOR, 8.4; 95% CI, 5.3–13.3; P < .001). HemBMT patients were also more likely to receive appropriate nonsurgical antibacterial prophylaxis compared to noncancer patients (OR, 3.1; 95% CI, 1.9–5.0; P < .001). However, in the Australian context, the hemBMT group had higher than expected use of fluoroquinolone prophylaxis (66 of 831 prescriptions, 8%). Conclusions: This study demonstrates why separate analysis of hemBMT and oncology populations is necessary to identify specific opportunities for quality improvement in each patient group.

Prognostic Indicators for Blood and Marrow Transplant Patients Admitted to an Intensive Care Unit

1998 ◽  
Vol 158 (3) ◽  
pp. 876-884 ◽  
Author(s):  
KRISTEN J. PRICE ◽  
PETER F. THALL ◽  
SUSANNAH K. KISH ◽  
VICKIE R. SHANNON ◽  
BORJE S. ANDERSSON
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Marrow Transplant ◽  
Prognostic Indicators ◽  
Transplant Patients ◽  
Blood And Marrow Transplant
Sign in / Sign up

Export Citation Format

Share Document